Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2014
|
| gptkbp:ATCCode |
gptkb:L01EM01
|
| gptkbp:blackBoxWarning |
yes
|
| gptkbp:brand |
gptkb:Zydelig
|
| gptkbp:CASNumber |
870281-82-6
|
| gptkbp:chemicalFormula |
C22H18FN7O
|
| gptkbp:eliminationHalfLife |
8.2 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:genericName |
gptkb:idelalisib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zydelig
|
| gptkbp:indication |
gptkb:small_lymphocytic_lymphoma
chronic lymphocytic leukemia follicular lymphoma |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Gilead_Sciences
|
| gptkbp:mechanismOfAction |
PI3K delta inhibitor
|
| gptkbp:metabolism |
gptkb:aldehyde_oxidase
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
84%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
infections hepatotoxicity inflammatory bowel disease pneumonitis |
| gptkbp:bfsParent |
gptkb:idelalisib
|
| gptkbp:bfsLayer |
5
|